Scinai Immunotherapeutics Ltd - ADR
SCNI
Get informed when a big investor buys or sells
+ FollowMarket Cap$591.92K
Close$
$1.67
267.8% upside
Current Fair Value
267.8% upsideUndervalued by 267.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $591,915.00 |
|---|---|
| Enterprise Value | $1.29 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.6 |
| Beta | 2.19 |
| Outstanding Shares | 2,334,865 |
Return
| Return on Equity | -102.52% |
|---|---|
| Return on Assets | -71.45% |
| Return on Invested Capital | -79.16% |
Valuation & Multiples
| P/E Ratio | -0.13 |
|---|---|
| PEG | -0.83 |
| Price to Sales | - |
| Price to Book Ratio | 0.15 |
| Enterprise Value to Revenue | 0.85 |
| Enterprise Value to EBIT | -0.16 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.83 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Scinai Immunotherapeutics Ltd
26 employees
CEO: Ron Babecoff biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and p...